Christina Ohnsman
Dr. Christina Ohnsman is Chief Medical Officer of Tern Therapeutics. Prior to cofounding Tern, Dr. Ohnsman was Executive Director of Clinical Development at REGENXBIO Inc., where she led global clinical development for rare ocular and CNS diseases, including CLN2 disease. Previously, as the founder of a biopharma communications and consulting firm, Dr. Ohnsman provided strategic guidance in clinical development, medical affairs, business development, commercialization, post-marketing development, and health economics and outcomes for ophthalmic life sciences clients. Her work with Spark Therapeutics on Luxturna™, the first gene therapy approved in the US for a genetic disease, ignited her passion for the curative potential of genetic treatments for rare diseases. Dr. Ohnsman began her career as the founder of a pediatric ophthalmology practice while serving on the faculty of Wills Eye Hospital in Philadelphia. She received her M.D. from UMDNJ-New Jersey Medical School and a B.A. from Drew University.
Abstracts this author is presenting: